646 related articles for article (PubMed ID: 32672401)
21. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains.
Ogura T; Tong KI; Mio K; Maruyama Y; Kurokawa H; Sato C; Yamamoto M
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):2842-7. PubMed ID: 20133743
[TBL] [Abstract][Full Text] [Related]
22. Dimethylfumarate alleviates early brain injury and secondary cognitive deficits after experimental subarachnoid hemorrhage via activation of Keap1-Nrf2-ARE system.
Liu Y; Qiu J; Wang Z; You W; Wu L; Ji C; Chen G
J Neurosurg; 2015 Oct; 123(4):915-23. PubMed ID: 25614941
[TBL] [Abstract][Full Text] [Related]
23. Crystal structure of the Kelch domain of human Keap1.
Li X; Zhang D; Hannink M; Beamer LJ
J Biol Chem; 2004 Dec; 279(52):54750-8. PubMed ID: 15475350
[TBL] [Abstract][Full Text] [Related]
24. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
Cheng L; Wang H; Li S; Liu Z; Wang C
Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.
Padmanabhan B; Tong KI; Ohta T; Nakamura Y; Scharlock M; Ohtsuji M; Kang MI; Kobayashi A; Yokoyama S; Yamamoto M
Mol Cell; 2006 Mar; 21(5):689-700. PubMed ID: 16507366
[TBL] [Abstract][Full Text] [Related]
26. Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).
Zhong M; Lynch A; Muellers SN; Jehle S; Luo L; Hall DR; Iwase R; Carolan JP; Egbert M; Wakefield A; Streu K; Harvey CM; Ortet PC; Kozakov D; Vajda S; Allen KN; Whitty A
Biochemistry; 2020 Feb; 59(4):563-581. PubMed ID: 31851823
[TBL] [Abstract][Full Text] [Related]
27. Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2.
He X; Ma Q
J Pharmacol Exp Ther; 2010 Jan; 332(1):66-75. PubMed ID: 19808700
[TBL] [Abstract][Full Text] [Related]
28. The molecular mechanism of Nrf2-Keap1 signaling pathway in the antioxidant defense response induced by BaP in the scallop Chlamys farreri.
Wang H; Pan L; Xu R; Si L; Zhang X
Fish Shellfish Immunol; 2019 Sep; 92():489-499. PubMed ID: 31220575
[TBL] [Abstract][Full Text] [Related]
29. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
30. Keap1-MCM3 interaction is a potential coordinator of molecular machineries of antioxidant response and genomic DNA replication in metazoa.
Tamberg N; Tahk S; Koit S; Kristjuhan K; Kasvandik S; Kristjuhan A; Ilves I
Sci Rep; 2018 Aug; 8(1):12136. PubMed ID: 30108253
[TBL] [Abstract][Full Text] [Related]
31. Negative regulation of the Nrf1 transcription factor by its N-terminal domain is independent of Keap1: Nrf1, but not Nrf2, is targeted to the endoplasmic reticulum.
Zhang Y; Crouch DH; Yamamoto M; Hayes JD
Biochem J; 2006 Nov; 399(3):373-85. PubMed ID: 16872277
[TBL] [Abstract][Full Text] [Related]
32. Steatotic Hepatocytes Release Mature VLDL Through Methionine and Tyrosine Metabolism in a Keap1-Nrf2-Dependent Manner.
Sano A; Kakazu E; Hamada S; Inoue J; Ninomiya M; Iwata T; Tsuruoka M; Sato K; Masamune A
Hepatology; 2021 Sep; 74(3):1271-1286. PubMed ID: 33724516
[TBL] [Abstract][Full Text] [Related]
33. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism.
Marcotte D; Zeng W; Hus JC; McKenzie A; Hession C; Jin P; Bergeron C; Lugovskoy A; Enyedy I; Cuervo H; Wang D; Atmanene C; Roecklin D; Vecchi M; Vivat V; Kraemer J; Winkler D; Hong V; Chao J; Lukashev M; Silvian L
Bioorg Med Chem; 2013 Jul; 21(14):4011-9. PubMed ID: 23647822
[TBL] [Abstract][Full Text] [Related]
34. Structural analysis of the complex of Keap1 with a prothymosin alpha peptide.
Padmanabhan B; Nakamura Y; Yokoyama S
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2008 Apr; 64(Pt 4):233-8. PubMed ID: 18391415
[TBL] [Abstract][Full Text] [Related]
35. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
Lee S; Abed DA; Beamer LJ; Hu L
SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
[TBL] [Abstract][Full Text] [Related]
36. Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.
Heightman TD; Callahan JF; Chiarparin E; Coyle JE; Griffiths-Jones C; Lakdawala AS; McMenamin R; Mortenson PN; Norton D; Peakman TM; Rich SJ; Richardson C; Rumsey WL; Sanchez Y; Saxty G; Willems HMG; Wolfe L; Woolford AJ; Wu Z; Yan H; Kerns JK; Davies TG
J Med Chem; 2019 May; 62(9):4683-4702. PubMed ID: 30973731
[TBL] [Abstract][Full Text] [Related]
37. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase.
Furukawa M; Xiong Y
Mol Cell Biol; 2005 Jan; 25(1):162-71. PubMed ID: 15601839
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators.
Ma B; Lucas B; Capacci A; Lin EY; Jones JH; Dechantsreiter M; Enyedy I; Marcotte D; Xiao G; Li B; Richter K
Bioorg Med Chem Lett; 2020 Feb; 30(4):126852. PubMed ID: 31898999
[TBL] [Abstract][Full Text] [Related]
39. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Lu MC; Ji JA; Jiang ZY; You QD
Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
[TBL] [Abstract][Full Text] [Related]
40. Chlorhexidine as a Keap1-Nrf2 inhibitor: a new target for an old drug for Parkinson's disease therapy.
Unni S; Deshmukh P; Krishnappa G; Bharath MMS; Padmanabhan B
J Biomol Struct Dyn; 2023; 41(12):5367-5381. PubMed ID: 35713597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
